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Abstract
Background: The multiple drug resistance protein (MDR1/P-glycoprotein) is overexpressed in
glia and blood-brain barrier (BBB) endothelium in drug refractory human epileptic tissue. Since
various antiepileptic drugs (AEDs) can act as substrates for MDR1, the enhanced expression/
function of this protein may increase their active extrusion from the brain, resulting in decreased
responsiveness to AEDs.
Methods: Human drug resistant epileptic brain tissues were collected after surgical resection.
Astrocyte cell cultures were established from these tissues, and commercially available normal
human astrocytes were used as controls. Uptake of fluorescent doxorubicin and radioactive-
labeled Phenytoin was measured in the two cell populations, and the effect of MDR1 blockers was
evaluated.
Frozen human epileptic brain tissue slices were double immunostained to locate MDR1 in neurons
and glia. Other slices were exposed to toxic concentrations of Phenytoin to study cell viability in
the presence or absence of a specific MDR1 blocker.
Results: MDR1 was overexpressed in blood vessels, astrocytes and neurons in human epileptic
drug-resistant brain. In addition, MDR1-mediated cellular drug extrusion was increased in human
'epileptic' astrocytes compared to 'normal' ones. Concomitantly, cell viability in the presence of
cytotoxic compounds was increased.
Conclusions: Overexpression of MDR1 in different cell types in drug-resistant epileptic human
brain leads to functional alterations, not all of which are linked to drug pharmacokinetics. In
particular, the modulation of glioneuronal MDR1 function in epileptic brain in the presence of toxic
concentrations of xenobiotics may constitute a novel cytoprotective mechanism.
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Background
Failure to respond to therapeutic concentrations of antie-
pileptic drugs (AEDs) is the usual basis for defining mul-
tiple drug resistant epilepsy, but the mechanisms
underlying resistance to AEDs are still largely unknown. It
is generally believed to be a multifactorial phenomenon,
depending on both pharmacodynamic and pharmacoki-
netic mechanisms. The electrical and synaptic properties
of neurons in epileptic human tissue are reported to
undergo changes that may result in decreased susceptibil-
ity to some AEDs [1]. Multidrug resistance in epilepsy may
also result from inadequate intraparenchymal AED con-
centrations due to poor penetration of the blood-brain
barrier (BBB).
Recent findings suggest that the molecular mechanisms of
clinically defined multiple drug resistance involve drug-
efflux transporters such as the ATP-binding cassette sub-
family B member 1 (ABCB1), also known as MDR1 or P-
glycoprotein (P-gp) [2-4]. Specifically, in epileptic brain,
genes associated with multiple drug resistance are overex-
pressed in the endothelial cells that constitute the BBB
[5,6]. MDR1 is also overexpressed in neurons [4,7] and
astrocytes (in which MDR1 is normally not measurable)
from lesions associated with active epileptogenic foci in
human and rodent brain [8-10].
The link between MDR1 overexpression and drug resist-
ance in epilepsy is still poorly understood [6,11]. Thus,
while localization of the drug extrusion pump in the BBB
is consistent with reduced penetration of AEDs into the
CNS, it is not known if or how the presence of MDR1 in
the parenchyma affects drug delivery and distribution, or
whether it is involved in different cellular functions. Evi-
dence from several groups suggests that MDR1 diminishes
the apoptotic response induced by growth factor with-
drawal [12], decreases complement-mediated cytotoxicity
([13] and impairs the activation of caspase-dependent cell
death pathways [14,15]. Reports indicate that all these
events occur in epileptic tissue, and they are thought to be
at least partly responsible for seizure-associated neuronal
cell death. In addition, we recently found that epileptic
astrocytes that overexpress MDR1 are devoid of p53, a
proapoptotic factor [8].
In this study we have evaluated the relationship between
neuronal and astrocytic MDR1 expression and the capac-
ity of the cells to survive cytotoxic insults, using drug
resistant epileptic human specimens. Our results suggest
that overexpression of MDR1 leads to functional altera-
tions in the CNS that may be linked to both drug pharma-
cokinetics and neuroglial survival in injured brain.
Methods
Human tissue
Human subjects were used as donors of cortical tissue
samples. The investigation conformed to the principles
outlined in the Declaration of Helsinki. Patient consent
was obtained as per Institutional Review Board instruc-
tions before collection of the specimens. All the experi-
ments involved small portions of human neocortical or
hippocampal tissue, which were excised for therapeutic
reasons from patients with pharmacoresistant epilepsy
(see Table 1 for patient identification). Temporal lobe tis-
sue was taken from the inferior or middle temporal gyrus
during standard temporal lobectomy; frontal or parietal
lobe samples were chosen from the most epileptogenic
areas, as determined by chronic subdural grid or intraop-
erative electrocorticographic (EEG) recordings. Handling
of the excised tissue depended on the experiment to be
conducted, as described below.
Table 1: Information on patients affected by various forms of epilepsy whose brain specimens were used for the experiments (ICC = 
Immunocytochemistry and Immunohistochemistry, TOX = Phenytoin toxicity, UP = drug uptake).
ID # Sex Age (years) Use Pathology
1 M 8 months ICC Parieto-Occipital-Frontal cortical dysplasia, Right Hemispherectomy
2 F 49 ICC Temporal Lobe Epilepsy, Hippocampal atrophy
3 F 10 ICC Left Hippocampal sclerosis
4 F 3 ICC Cortical Dysplasia, Right Hemispherectomy
5 M 7 ICC Left Cortical Dysplasia
6 F 4 ICC Right Frontoparietal Epilepsy
7 M 1 ICC Left Frontal Lobe Epilepsy
8 M 25 ICC Right Temporal Lobe Epilepsy
9 M 45 TOX, ICC Temporal Lobe Epilepsy
10 F 4 TOX, ICC Cortical Dysplasia
11 F 36 TOX, ICC Temporal Lobe Epilepsy
12 M 24 UP Left Frontal Lobe Epilepsy
13 F 14 UP Cortical Dysplasia
14 M 7 UP Left Temporal/Frontoparietal EpilepsyBMC Medicine 2004, 2:37 http://www.biomedcentral.com/1741-7015/2/37
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Cell isolation and primary cultures
Astrocyte cell cultures were established, as described by
Marroni et al. [8,9,16], from cerebral cortical tissue
obtained during temporal lobectomies (n = 3) conducted
to relieve medically intractable seizures (see Table 1 for
details on patients, ID# 12, 13, 14). The cells were pas-
saged up to three times before use. MDR1 expression was
not affected by the number of passages [8,9,16].
Commercially available normal human astrocytes were
used as controls (ACBRI 371, Applied Cell Biology
Research Institute, Kirkland, WA, USA, and Clonetics, Bio-
whitaker, Walkersville, MD, USA).
Immunohistochemistry
To investigate MDR1 protein expression and cellular dis-
tribution in human epileptic tissue, slide-mounted sec-
tions (10 µm thickness) from frozen brain tissue (Table 1,
patient ID# 1–11; 3 slices per patient) were double immu-
nostained as previously described [8,9,16]. The primary
antibodies used were mouse monoclonal anti-P-Glyco-
protein (C494) (1:40, Calbiochem-Novabiochem Corpo-
ration, San Diego, CA, USA), human polyclonal anti-P-
Glycoprotein (1:100, Calbiochem-Novabiochem Corpo-
ration, San Diego, CA, USA), mouse monoclonal anti-
neuronal nuclei (NeuN) (1:500, Chemicon International,
Temecula, CA, USA), rabbit polyclonal anti-neurofila-
ment (NF) (1:200, Chemicon International, Temecula,
CA, USA) and rabbit anti-cow glial fibrillary acidic protein
(GFAP) (1:200, DAKO Corporation, Carpinteria, CA,
USA). Secondary antibodies were chosen according to the
primary antibody hosts: Texas red dye-conjugated affin-
ipure donkey anti-mouse IgG (1:50, Jackson Immunore-
search Laboratories Inc., West Grove, PA, USA), and
Fluorescein isothiocyanate (FITC)-conjugated affinipure
donkey anti-mouse and anti-rabbit IgG (1:200, Jackson
Immunoresearch Laboratories Inc., West Grove, PA,
USA). Sections were coverslipped on glass slides using
Vectashield mounting medium with DAPI (Vector, Burl-
ingame, CA, USA) and analyzed by fluorescent
microscopy.
Cell counting
For quantitative evaluation of neurons and astrocytes
expressing MDR1 in epileptic tissue, we chose three 1600
µm2 fields at random in each tissue slice (3 slices per
patient, n = 11 patients; see Table 1, patient ID# 1–11).
Within each field, NeuN or GFAP positive cells co-express-
ing MDR1 were counted using NIH Software and Pho-
toshop 6 (Adobe), and the number was expressed as a
fraction of the total number of neurons and astrocytes,
respectively, in that field. Numbers for each field were
then averaged for every slice, and the mean value for each
patient is given in Fig. 1B,1D.
Doxorubicin uptake
Astrocytes from epileptic tissue (Table 1, patient ID# 12,
13, 14) or commercially available control human astro-
cytes were cultured in 8-well chamber-slides. At conflu-
ence, the cells (approximately 8 × 104 per well) were
treated overnight with 1µM XR9576, a specific MDR1
blocker [17,18], or for 2 h with 50 µM verapamil, a non-
specific MDR1 blocker [19,20]. Further sets of astrocytes
from epileptic tissue and controls were incubated as above
but in the absence of blockers. Fluorescent red doxoru-
bicin [21] was then added to all the cultures for 1, 2, 3, 5,
7 and 24 h. Incubation was stopped by rinsing twice with
PBS and the cells were fixed overnight at 4°C in 4% for-
malin in PBS (pH 7.4). They were mounted and cover-
slipped the next day using Vectashield mounting
medium. Doxorubicin uptake was analyzed by fluores-
cent microscopy (Leica Leitz DM-RXE, Wetzlar, Germany)
using NIH Image Software. For each well, four fields
(1600 µm2) were randomly analyzed and optical density
measurements were averaged to obtain representative
data. To quantify the doxorubicin in the cells, the
fluorescence in each sample was compared with standard
solutions of doxorubicin (10 nM-10 µM). Data were ana-
lyzed using Origin Lab 7 software.
14C-Phenytoin uptake
14C-Phenytoin uptake was measured in cultured astro-
cytes from epileptic tissue (Table 1, patient ID# 12, 13,
14) and in control astrocytes, as described by Meyer et al.
[22]. The cells were cultured in 30-mm Petri dishes
(approximately 106 cells) and incubated at 37°C with 1
ml of T3 cell buffer (Tris-HCl 50 mM, NaCl 120 mM, KCl
50 mM, pH 7.4) containing 10 µM 14C-Phenytoin (Spe-
cific activity = 9.57 µCi/µmol). The incubation was termi-
nated after 10 s, 30 s, 1 min, 5 min or 10 min by adding 1
ml of ice-cold T3 buffer. The cells were washed with 1 ml
of ice-cold T3 buffer and solubilized with 1% (w/v) Triton
X-100 for 1 h at 37°C. Intracellular radioactivity was
measured using a scintillation cocktail (Packard Ultima
Gold, ECN, Costa Mesa, CA, USA).
Acute in vitro toxicity
Brain slices (500 µm) were cut using a vibratome from
dysplastic human cortex and temporal lobe epilepsy brain
specimens (Table 1, patient ID# 9,10,11). Slices (n = 6 per
patient) were maintained in vitro as previously described
[23,24]. A further set of 6 slices was obtained from 3 naïve
rats as previously described [25]. Slices (n = 2 per patient
per experimental condition) were incubated for 2 h in
artificial CSF containing, in mM: NaCl 124; KCl 3; CaCl2
1; MgCl2 1.4; NaHCO3
- 26; KH2PO4 1.25; glucose 10, with
or without 3 µM XR9576. A toxic concentration (375 µM)
of Phenytoin (PHE) was then added for 5 h [22]. An addi-
tional set of slices was kept for 7 h in artificial CSF only,
and electrophysiological measurement of activity wasBMC Medicine 2004, 2:37 http://www.biomedcentral.com/1741-7015/2/37
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Immunohistochemical detection of MDR1 expression in human drug-refractory epileptic brain Figure 1
Immunohistochemical detection of MDR1 expression in human drug-refractory epileptic brain. Panels A-B show 
MDR1 expression at the BBB. Widespread GFAP immunoreactivity (green) co-localizes with MDR1 (red). Nuclei are stained 
blue with DAPI. Note that both parenchymal and perivascular astrocytes express MDR1 (arrowheads), as do endothelial cells 
of the brain capillaries (thin arrows). The box graph in B illustrates the percentage of GFAP-positive astrocytes (GFAP) in sam-
ples from 11 patients (Table 1, 1–11) that also expressed MDR1. Data points (circles), mean value (triangle), range (horizontal 
bars) and standard errors (° SE) are shown together with the 50th percentile value. Panels C-D show the neuronal expression 
of MDR1. Double immunostaining with MDR1 and two neuronal markers (neurofilament, NF and NeuN) reveals that MDR1 is 
expressed in a subpopulation of epileptic neurons. Arrows point to MDR1 negative neurons, while arrowheads indicate the more 
frequently-occurring MDR1 positive neurons. Approximately 64% of cortical neurons (n = 264) were positive for MDR1. 
Quantitative analysis in D was obtained from 11 patients. Patient values (circles), mean (triangle), range (horizontal bars) and 
standard errors (± SE) are shown. The 50th percentile is also indicated in the box graph.BMC Medicine 2004, 2:37 http://www.biomedcentral.com/1741-7015/2/37
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used to assess tissue viability throughout the experiment.
Live/Dead Viability/Cytotoxicity solution (Molecular
Probes L3224, Eugene, OR, USA) was used to quantify cell
death or survival; EthD-1, a component of the solution,
enters cell nuclei through damaged membranes, produc-
ing a bright red fluorescence in dead cells. The 2 mM
EthD-1 stock solution (20 µl) was added to 10 ml of 1X
sterile PBS. At the end of the experiment, each slice was
washed with PBS and incubated with 2 ml of the above
solution for 10 min under continuous oxygenation. The
slices were then fixed in 4% formalin in PBS overnight at
4°C and cryoprotected by 30% sucrose. Three 20 µm
slices were cryosectioned from each 500 µm slice and ana-
lyzed by fluorescent microscopy. DAPI was used to assess
the total number of cells per slice, and GFAP and NeuN
were used to identify glia and neurons (see 'Immunohis-
tochemistry'). The number of EthD-1 positive cells was
reckoned in 3 randomly chosen fields (1600 µm2) within
each slice. These values were averaged for each slice and
expressed as percentages of the average number of DAPI-
positive cells in the chosen fields.
Evaluation of glioneuronal damage
To evaluate the relationship between MDR1 positive cells
and nuclear morphology (DAPI staining), 10 µm slices
from 11 patients (Table 1, patient ID# 1–11) were
obtained as described in 'Immunocytochemistry'. Small
and condensed nuclei indicate apoptosis or irreversible
cell damage, while large nuclei with diffuse DNA (DAPI)
staining are typical of healthy cells. MDR1 positive cells
with diffuse DNA staining (healthy cells) were counted
over three randomly chosen fields in each slice and ana-
lyzed using NIH Software and Photoshop. Numbers for
each field were averaged for every slice; the corresponding
mean value is given in figure 3B.
Statistical analysis of data
Data were expressed as means ± SEM. The level of signifi-
cance between means was estimated by ANOVA (Origin
6.0. Microcal). Differences with p < 0.05 were considered
significant.
Results
Results were obtained from 14 patients (50% female)
affected by intractable seizures. The mean patient age was
16.4 years (range 8 months – 49 years; SE = 4.6). For
details, see Table 1.
MDR1 expression in human epileptic brain tissue
Figure 1 shows representative micrographs of MDR1
expression in endothelial, glial and neuronal cells from
epileptic human brain specimens (Table 1, patient ID# 1–
11). The findings are consistent with previous work dem-
onstrating that MDR1 expression in multiple drug resist-
ant brains is confined to the cortical lesion site [4,7-9,16];
this was consistently observed in all epileptic samples in
the present study. Thus, relatively normal brain distant
from the dysplastic tissue can be used as "control". Abun-
dant MDR1 immunopositive endothelial cells (thin arrows
in A) were observed in epileptic cortex, as well as immu-
nopositive parenchymal and perivascular astrocytes
(arrowheads in A) double-labeled with GFAP, a specific
glial marker. Out of 107 GFAP-positive astrocytes, 91
(85%) showed MDR1 staining (Figure 1B). We also exam-
ined MDR1 expression in neurons from epileptic tissue,
identified by NeuN and NF immunoreactivity (Fig. 1C).
Approximately 169 out of 264 NeuN-positive neurons
(64%) showed MDR1 staining (Figure 1D).
Role of MDR1 expression in drug extrusion by astrocytes
To determine whether MDR1 expression in 'epileptic'
astrocytes results in enhanced extrusion of xenobiotics
compared to 'normal' astrocytes, we measured the cellular
uptake of PHE and doxorubicin, two established sub-
strates of P-glycoprotein [19,20,26,27] (Table 1, patient
ID# 12, 13, 14; Fig. 2). We used 1 µM red fluorescent dox-
orubicin [21] and visualized its cellular distribution by
fluorescent microscopy (Fig. 2A). We previously showed
by western blot analysis that 'normal' astrocytes have
lower levels of P-gp than 'epileptic' astrocytes [8,9]. Dox-
orubicin uptake was reduced in astrocytes from epileptic
tissue compared to control astrocytes (p < 0.05). This
effect was abolished by the specific blocker XR9576 (1
µM) [17,18], or by the less specific antagonist verapamil
(50 µM), indicating active MDR1-mediated extrusion of
doxorubicin by epileptic glia.
Fig. 2B shows that uptake of 10 µM 14C-Phenytoin was sig-
nificantly lower in astrocytes from epileptic tissue than in
control astrocytes, and the difference was maximal after
10 min incubation with the AED (p < 0.05). The
difference was abolished in the presence of 1 µM XR9576,
indicating MDR1-mediated efflux of PHE in epileptic
astrocytes. The MDR1 blockers did not affect doxorubicin
or Phenytoin uptake in control astrocytes (not shown).
Neither Phenytoin nor doxorubicin treatment induced
toxicity in cell cultures under our experimental
conditions.
MDR1 and cell survival
MDR1 is involved in detoxification mechanisms that pro-
tect cells from xenobiotics [28], apoptosis [12] and other
cellular stresses [13-15]. To investigate whether MDR1
expression in astrocytes and neurons from epileptic tissue
enhances survival of toxic or injurious events, we exposed
neocortical slices from human epileptic (Table 1, patient
ID# 9, 10, 11) and rat brain to concentrations of PHE
higher than those reported to induce toxicity in cultured
rat astrocytes [22]. Bar histograms (Figure 3A) indicate
that slices of human epileptic cortex exposed for 5 h toBMC Medicine 2004, 2:37 http://www.biomedcentral.com/1741-7015/2/37
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375 µM PHE showed no cellular toxicity, as assessed by
co-localization of the nuclear marker DAPI with EthD-1, a
marker of cell damage. Conversely, significant cell loss (p
< 0.05) was observed in rat brain slices under these exper-
imental conditions. When MDR1 activity was blocked by
3 µM XR9576, PHE induced cell damage in the human
epileptic cortex to an extent similar to that in rat brain tis-
sue. Neurons and astrocytes, identified using NeuN and
GFAP respectively, were similarly affected by PHE (Fig.
3A). The MDR1 inhibitor XR9576 alone (3µM) did not
affect tissue viability (data not shown).
Figure 3B shows a significant positive correlation (R = 0.4,
p < 0.006) between MDR1 expression and cell integrity, as
Glioneuronal MDR1 expression and resistance to Phenytoin induced cytotoxicity Figure 3
Glioneuronal MDR1 expression and resistance to Phenytoin induced cytotoxicity. Histograms in A show data 
(mean ± SE, n = 3) obtained using cortical slices from human epileptics (Table 1, ID# 9,10,11), or naïve rat cortical slices, 
treated for 5 h with 375 µM Phenytoin (PHE) ± 2 h preincubation with 3 µM XR9576. Note that PHE toxicity (as illustrated in 
the micrographs) was apparent in normal rat brain slices, and was greatly exacerbated in human epileptic tissue treated with 
the MDR1 blocker (p < 0.01). Micrographs depict immunohistochemical evidence of PHE-induced cytotoxicity in GFAP-posi-
tive astrocytes and NeuN-positive neurons as assessed by their co-localization with EthD-1, a marker of cell damage. All the 
cells (astrocytes and neurons) were assessed by DAPI staining. Note that the combination of PHE + XR9576 increased the 
percentage of injured cells (red) as compared to PHE alone. Panel B shows enlarged nuclei (identified by DAPI) in cells express-
ing (MDR1 positive) or not expressing (MDR1 negative) MDR1 protein. Note that small condensed nuclei (seen in MDR1 neg-
ative cells) reflect apoptosis or irreversible cell damage. In contrast, large nuclei with diffuse DNA staining (seen in MDR1 
positive cells) are typical of healthy cells. The graph shows the positive correlation between cells with healthy nuclei and MDR1 
expression (n = 34 independent values from slices obtained from 11 patients; p < 0.006).BMC Medicine 2004, 2:37 http://www.biomedcentral.com/1741-7015/2/37
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measured by morphological evaluation of nuclear con-
densation (DAPI staining) [29,30]. Quantification of the
cells retaining nuclear DNA integrity showed that no DNA
damage occurred in 85% of glia and 66% of neurons
expressing MDR1, suggesting a novel role for MDR1 in
protecting neurons and glia from toxic agents.
Discussion
The main finding was that MDR1 might have different
roles depending on the location in the brain where it is
expressed. Thus, in addition to overexpression in
endothelial cells, which is likely to affect the penetration
of AEDs into the brain, MDR1 is also overexpressed in the
parenchyma, where it might have a cytoprotective role,
Uptake of doxorubicin and phenytoin by astrocytes: effect of MDR1 blockade Figure 2
Uptake of doxorubicin and phenytoin by astrocytes: effect of MDR1 blockade. Panel A shows 1 µM doxorubicin 
uptake in astrocytes from epileptic human brain (n = 3 patients) and controls. Note that uptake was decreased in "epileptic" 
astrocytes compared to normal astrocytes, and this difference was abolished when MDR1 inhibitors (1 µM XR9576 or 50 µM 
verapamil) were added. Micrographs depict red fluorescent doxorubicin uptake in the various experimental conditions as 
assessed by fluorescence microscopy. Panel B shows the time-course of intracellular accumulation of 14C-Phenytoin in "epilep-
tic" astrocytes and controls. Note that 14C-Phenytoin uptake into epileptic astrocytes reached a plateau after 10 s incubation, 
while uptake in control astrocytes was greater at each time point and reached a plateau after 10 min incubation (p < 0.01 vs. 
control; n = 3). 14C-Phenytoin uptake in "epileptic" astrocytes returned to control level in the presence of 1 µM XR9576 (°p < 
0.01 vs. control''; ^p < = 0.01 vs. "epileptic'' astrocytes+XR9576).BMC Medicine 2004, 2:37 http://www.biomedcentral.com/1741-7015/2/37
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extruding otherwise toxic concentrations of xenobiotics
from the intracellular compartment.
MDR1 expression in epileptic brain
In agreement with previous findings, we report here that
MDR1 is highly expressed in vessels of the BBB and in
parenchymal cells (histochemically identified as astro-
cytes and neurons) in drug refractory epilepsy of different
etiologies [4,7-9,11,27]. Pharmacological evidence
suggests that MDR1 overexpression in blood vessels of the
BBB has the crucial role of extruding AEDs from brain to
blood [19,20,27,31], and this phenomenon may contrib-
ute to failure of antiepiletic treatments. In this study, we
focused on the effects of MDR1 expression in parenchy-
mal neurons and astrocytes from pharmacoresistant epi-
leptic tissue.
Model of the proposed role of cell specific MDR1 expression in epileptic brain Figure 4
Model of the proposed role of cell specific MDR1 expression in epileptic brain. Under physiological conditions, when 
the blood-brain barrier is intact, overexpression of MDR1 (and possibly other drug resistance proteins [5,9]) in endothelial 
cells causes active net extrusion of drugs from the brain into the vascular lumen (left panel, (1)). A fraction of the AED mole-
cules bypassing the MDR1 barrier (see Fig. 1A) will diffuse into the lipophilic membranes of parenchymal neurons and glia. 
MDR1 expression in these cells will lead to diminished intracellular sequestration of drugs and may increase their interstitial 
levels [27]. However, since the total amount of AED in the epileptic tissue is reduced in the first instance by active BBB extru-
sion, free AED in the extracellular space may still remain below therapeutic concentrations (left panel, (2) and (4)). In addition, 
MDR1 overexpression in parenchymal astrocytes and neurons affords protection against toxic concentrations of xenobiotics 
(left panel (2) and (4)). During the transient opening of the BBB due to epileptic activity, AEDs may be back-fluxed into the 
blood stream by MDR1 expressed at the glial end-feet of perivascular astrocytes, constituting a "second defense barrier" in the 
brain (left panel, (3)). Right panels A and B schematically summarize these possible roles of MDR1 in epileptic human brain.BMC Medicine 2004, 2:37 http://www.biomedcentral.com/1741-7015/2/37
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MDR1 expression in astrocytes: drug uptake studies
We found that PHE and doxorubicin uptake by astrocytes
from human epileptic tissue is reduced in comparison
with normal astrocytes. The difference is abolished when
MDR1 function is blocked, indicating that these drugs are
efficiently extruded by "epileptic" astrocytes by a P-gp
mediated mechanism. We suggest that this might contrib-
ute to decreasing the AED brain levels only if it occurs in
perivascular astrocytes. Thus, perivascular  astrocytes
impinging on blood vessels may act as an additional bar-
rier to drug penetration into the brain in regions where
BBB permeability is transiently altered, for example dur-
ing epileptic activity [32,33] (Fig. 4). In contrast, MDR1
overexpression by parenchymal glia would result in
enhanced extrusion of substrates into the brain extracellu-
lar space; this is not compatible with a decrease in the con-
centration of AEDs at their neuronal targets, suggesting
that it subserves a different function (see below).
MDR1 expression in neurons and parenchymal glia: 
relationship to cell survival
We show in this paper that MDR1 is expressed in immu-
nocytochemically identifiable neurons and astrocytes in
brain slices from refractory human epilepsy patients. We
have previously reported that basic apoptotic mechanisms
may be defective in glia from epileptic tissue, since the
pro-apoptotic proteins p53 and p21 could not be detected
in "epileptic" astrocytes [8,9,16]. This evidence, together
with overexpression of MDR1, suggests that "epileptic"
astrocytes have gained a distinct survival advantage. This
is supported by the marked enhancement of Phenytoin
cytotoxicity in both glia and neurons when MDR1 func-
tion is blocked. The conclusion is consistent with the find-
ings of Bittigau et al. [34] that various AEDs induce
apoptotic neuronal cell death in developing naïve rat
brain at plasma concentrations relevant to seizure control
in humans; activators of MDR1 transcription prevented
these effects.
Finally, we found a positive correlation between neuronal
and astrocytic expression of MDR1 and lack of nuclear
condensation, a marker of apoptosis and irreversible cell
damage. Thus, expression of MDR1 in glia and neurons
may protect the cells against toxic xenobiotics or against
endogenous compounds that enter the brain in patholog-
ical conditions.
Conclusions
In conclusion, as summarized in figure 4, our findings
indicate a possible new function for MDR1. In normal
brain, MDR1 operates at the blood-brain barrier, regulat-
ing the plasma/brain exchange of xenobiotics. In epileptic
brain, the levels of astrocytic, neuronal and endothelial
MDR1 are abnormal, possibly leading to altered brain
penetration/distribution of drugs. Perivascular astrocytes
may also contribute to this phenomenon. In addition to
its drug extrusion effect at the BBB, which may be relevant
for pharmacoresistance in epilepsy, this protein may have
a role in neuroglial survival under hostile conditions such
as those occurring in epileptic brain. The overexpression
of multiple drug resistance could be the consequence of
an altered mechanism of apoptotic cell death; this
hypothesis is supported by the finding that changes in
multiple drug resistance gene expression correlate with
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